Eric Tomlinson DSc, PhD
Eric Tomlinson, DSc, PhD is Chief Innovation Officer of Wake Forest Baptist Medical Center and President of Wake Forest Innovation Quarter.
Tomlinson comes to Winston-Salem to accelerate the creation and commercialization of innovative products, discoveries, and services arising from the clinical and academic base at the Medical Center and Wake Forest University and to lead the formation of a knowledge-based economy centered on the Quarter and its partners in developing a dynamic place to work, live and play.
Wake Forest Innovation Quarter in Winston-Salem, North Carolina is one of the largest urban research parks in the United States focused on research and innovation in bio- and life-science, information technology, and the arts, and is designated as the top economic project of the region. Wake Forest Baptist Medical Center includes the medical education and research components of Wake Forest School of Medicine, which is ranked among the nation’s best medical schools and is a leading national research center in several fields, including regenerative medicine, cancer, neuroscience, metabolism, aging, addiction, and public health sciences.
Dr. Tomlinson has a background as a scientific and business leader working both in early-stage and clinical stage biotechnology companies and within a global pharmaceutical company. He has built companies and teams from their inception and fund-raising - to their development of biological and small drug / device combination products and gene therapy products. He has transacted mergers of publicly traded companies and raised both private and public equity corporate financings in addition to broad-based product licensing and commercialization agreements with major pharmaceutical companies.
Tomlinson has held academic appointments in the U.S. and in Europe, including at the University of Amsterdam as professor in the department of pharmacy (1979-1983). He is (co)-author of 230 research publications in the life sciences and the pharmaceutical sciences (solution thermodynamics, drug design, site-specific drug delivery and gene therapy). He is a founder of Metaclipse Therapeutics Corporation an early-stage company developing patient- and tumor-specific immunotherapies for treating cancers and currently serves as Chairman of its Board of Directors.